Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
about
Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeMolecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniaeIncreasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasisIn vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanismsPharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae.
P2860
Q33807463-FAF5E202-EE1C-40A9-AE7A-7907950306FDQ33980747-FF2FD687-03A3-4A99-A260-49B1E434006AQ33983643-84B2DAC2-3EAC-4133-9D6F-22F5C05480F9Q35635780-75866B77-DDF3-4B1E-9CD2-A21C8585603BQ36009308-1DEC9BDA-9D23-40F8-ACA6-32FD22BE0380Q36482793-115B0E11-100A-426A-8E7C-083735558E35Q37488687-C9476D83-3436-4F4A-BEE3-DD07A01C67EFQ37568953-F9CD4D11-367A-49E3-BBE3-12D3A79E6056Q37733449-042F8FEC-7E87-4768-B4B1-3A8E6CC20280Q38455501-78D16F2D-0762-47F6-8E9A-F2D450D1A17CQ39478835-B3185B18-EAD1-4174-8B10-E055B024CFC1Q39537237-F48024C8-4FDB-46D7-914F-1840C1F9E28EQ39651301-343777E0-7F00-4586-801B-94ACC0A4812DQ39651324-2DB4A1D3-0879-43FA-9DA7-05FAC6178B58Q39743472-FE179BF8-7C2B-42C0-9BAB-98D6FCDDD2B1Q41840910-66D6E7BB-319D-42CB-91A5-03B8114B4888Q41854694-67B140BC-8B99-4D60-B6AE-DC856BED7FAAQ43112313-2CA6B034-DD6E-4E92-A090-245EB734686CQ47138989-4D3FDA3E-C1F6-4EF5-8FF8-2BCDE0AB6639
P2860
Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Activities of fluoroquinolones ...... rified as recombinant proteins
@en
Activities of fluoroquinolones ...... ified as recombinant proteins.
@nl
type
label
Activities of fluoroquinolones ...... rified as recombinant proteins
@en
Activities of fluoroquinolones ...... ified as recombinant proteins.
@nl
prefLabel
Activities of fluoroquinolones ...... rified as recombinant proteins
@en
Activities of fluoroquinolones ...... ified as recombinant proteins.
@nl
P2860
P1476
Activities of fluoroquinolones ...... rified as recombinant proteins
@en
P2093
P2860
P304
P407
P577
1999-11-01T00:00:00Z